{"nctId":"NCT01032629","briefTitle":"CANVAS - CANagliflozin cardioVascular Assessment Study","startDateStruct":{"date":"2009-12-09","type":"ACTUAL"},"conditions":["Diabetes Mellitus, Type 2","Cardiovascular Diseases","Risk Factors"],"count":4330,"armGroups":[{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]},{"label":"Canagliflozin (JNJ-28431754) 100 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Canagliflozin (JNJ-28431754) 100 mg"]},{"label":"Canagliflozin (JNJ-28431754) 300 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Canagliflozin (JNJ-28431754) 300 mg"]}],"interventions":[{"name":"Placebo","otherNames":[]},{"name":"Canagliflozin (JNJ-28431754) 100 mg","otherNames":[]},{"name":"Canagliflozin (JNJ-28431754) 300 mg","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patients must have a diagnosis of type 2 diabetes mellitus and greater than or equal to (\\>=) 30 yrs old with history of cardiovascular (CV) event, or \\>= 50 yrs old with high risk of CV events\n* Patients must have inadequate diabetes control (as defined by glycosylated hemoglobin greater than or equal to 7.0% to less than or equal to 10.5% at screening) and be either (1) not currently on diabetes drug therapy or (2) on therapy with any approved class of diabetes drugs\n\nExclusion Criteria:\n\n* A history of diabetic ketoacidosis, type 1 diabetes mellitus, pancreas or beta-cell transplantation, or diabetes secondary to pancreatitis or pancreatectomy\n* History of one or more severe hypoglycemic (ie, very low blood sugar) episode within 6 months before screening","healthyVolunteers":false,"sex":"ALL","minimumAge":"30 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Major Adverse Cardiovascular Events (MACE) Composite of Cardiovascular (CV) Death, Non-Fatal Myocardial Infarction (MI), and Non-Fatal Stroke","description":"MACE, defined as a composite of CV death, non-fatal MI, and nonfatal stroke. Adjudication of these events by the Endpoint Adjudication Committee (EAC) was performed in a blinded fashion. Event rate estimated based on the time to the first occurrence of MACE are presented.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"30.36","spread":null},{"groupId":"OG001","value":"28.41","spread":null},{"groupId":"OG002","value":"25.37","spread":null},{"groupId":"OG003","value":"26.89","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Homeostasis Model Assessment 2 Steady-State Beta-Cell Function (HOMA2-%B) at the End-of-Treatment (EOT)","description":"The homeostatic model assessment (HOMA) quantifies insulin resistance and beta-cell function. HOMA2-%B is a computer model that uses fasting plasma insulin and glucose concentrations to estimate steady-state beta cell function (%B) as a percentage of a normal reference population (normal young adults). The normal reference population was set at 100 percent.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.02","spread":"1.611"},{"groupId":"OG001","value":"6.82","spread":"1.533"},{"groupId":"OG002","value":"8.09","spread":"1.587"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Progression of Albuminuria at the End-of-Treatment","description":"Progression defined as the development of micro-albuminuria (albumin/creatinine ratio (ACR) greater than or equal to \\[\\>=\\] 30 milligram per gram (mg/g) and less than or equal to \\<= 300 mg/g) or macroalbuminuria (ACR of \\>300 mg/g) in a participant with baseline normoalbuminuria or the development of macro-albuminuria in a participant with baseline microalbuminuria. Percentage of participants with progression of albuminuria at the end-of-treatment were assessed.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"24.0","spread":null},{"groupId":"OG001","value":"20.2","spread":null},{"groupId":"OG002","value":"18.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Proinsulin/Insulin (PI/I) Ratio at the End-of-Treatment","description":"A raised proinsulin-to-insulin ratio due to impaired processing of proinsulin is an early marker of beta cell dysfunction. Beta-cell dysfunction was evaluated by calculating the PI/I ratio, which estimates the capacity of beta cells to convert proinsulin to insulin and may represent an acceptable method to indicate the degree of beta-cell secretion.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.70","spread":"0.150"},{"groupId":"OG001","value":"0.67","spread":"0.140"},{"groupId":"OG002","value":"1.03","spread":"0.142"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Urinary Albumin/Creatinine Ratio at End-of-Treatment","description":"Urinary Albumin/Creatinine Ratio is a potential marker of chronic kidney disease, calculated as a ratio of Urinary Albumin and Urinary Creatinine.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"29.30","spread":null},{"groupId":"OG001","value":"25.50","spread":null},{"groupId":"OG002","value":"24.47","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) at End-of-Treatment","description":"Change from baseline in Estimated Glomerular Filtration Rate (eGFR) was assessed at end of treatment. GFR is a measure of the rate at which blood is filtered by the kidney. Modification of Diet in Renal Disease (MDRD) is an equation (calculation) used to estimate GFR in participants with impaired renal function based on serum creatinine, age, race, and sex. eGFR milliliters/minute/1.73 meters square (mL/min/1.73 m\\^2) = 175 \\* (serum creatinine) \\^ 1.154 \\* (Age) \\^-0.203 \\*(0.742 if female) \\* (1.21 if Black).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.23","spread":"0.390"},{"groupId":"OG001","value":"-3.55","spread":"0.388"},{"groupId":"OG002","value":"-3.98","spread":"0.392"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Glycated Hemoglobin (HbA1c) at End-of-Treatment","description":"Change from baseline in glycated hemoglobin (HbA1c) percentage (%) was assessed at end of treatment. Glycated hemoglobin is a form of hemoglobin that is measured primarily to identify the average glucose concentration in the blood.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.01","spread":"0.032"},{"groupId":"OG001","value":"-0.26","spread":"0.032"},{"groupId":"OG002","value":"-0.31","spread":"0.032"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Fasting Plasma Glucose (FPG) Levels at End-of-Treatment","description":"Change from baseline in the fasting plasma glucose levels at end-of-treatment was assessed.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.16","spread":"0.076"},{"groupId":"OG001","value":"-0.42","spread":"0.075"},{"groupId":"OG002","value":"-0.57","spread":"0.076"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Body Weight at End-of-Treatment","description":"Percent change from baseline in body weight was assessed at the end of treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.50","spread":"0.184"},{"groupId":"OG001","value":"-3.47","spread":"0.183"},{"groupId":"OG002","value":"-4.12","spread":"0.185"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at End-of-Treatment","description":"Change from baseline in systolic blood pressure and diastolic blood pressure was assessed.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.96","spread":"0.377"},{"groupId":"OG001","value":"-4.91","spread":"0.375"},{"groupId":"OG002","value":"-6.49","spread":"0.378"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.88","spread":"0.223"},{"groupId":"OG001","value":"-3.70","spread":"0.221"},{"groupId":"OG002","value":"-4.51","spread":"0.223"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Triglycerides Levels at End-of-Treatment","description":"Change from baseline in triglycerides levels was assessed.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.05","spread":"1.597"},{"groupId":"OG001","value":"0.13","spread":"1.679"},{"groupId":"OG002","value":"0.09","spread":"1.238"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Cholesterol, High-Density Lipoprotein Cholesterol (HDL-C) and Low Density Lipoprotein Cholesterol (LDL-C) Levels at End-of-Treatment","description":"Change from baseline in cholesterol, high-density lipoprotein cholesterol and low density lipoprotein cholesterol levels were assessed.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.07","spread":"0.028"},{"groupId":"OG001","value":"0.11","spread":"0.027"},{"groupId":"OG002","value":"0.16","spread":"0.028"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.01","spread":"0.006"},{"groupId":"OG001","value":"0.04","spread":"0.006"},{"groupId":"OG002","value":"0.05","spread":"0.006"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.07","spread":"0.022"},{"groupId":"OG001","value":"0.04","spread":"0.022"},{"groupId":"OG002","value":"0.10","spread":"0.023"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Low-Density Lipoprotein-Cholesterol (LDL-C) to High-Density Lipoprotein-Cholesterol (HDL-C) Ratio at End-of-Treatment","description":"Change from baseline in LDL-C to HDL-C ratio was assessed.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.04","spread":"0.021"},{"groupId":"OG001","value":"-0.02","spread":"0.021"},{"groupId":"OG002","value":"0.00","spread":"0.021"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":584,"n":1441},"commonTop":["Nasopharyngitis","Hypoglycaemia","Upper Respiratory Tract Infection","Back Pain","Urinary Tract Infection"]}}}